None of the 29 investors followed here reported a position in PLYX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PLYX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 26, 2026 | Yang Alex Keun MoChief Executive Officer | Purchase at price 2.51 per share. | 88.5K | $222.02K |
| Feb 17, 2026 | Landis G MichaelChief Financial Officer | Purchase at price 2.79 per share. | 2.9K | $7.99K |
Buy / hold / sell counts
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.